Abstract
Influenza is a major burden to public health. Due to high mutation rates and selection pressure, mutant viruses emerge which are resistant to currently used antiviral drugs. Therefore, there is a need for the development of novel classes of antiviral drugs that suffer less from the emergence of resistant viruses. Antiviral drugs based on collectin-like surfactant protein D (SP-D) may fulfil these requirements. Especially porcine SP-D displays strong antiviral activity to influenza A viruses. In the present study the antiviral activity of recombinant porcine SP-D was investigated in ex vivo cultures of respiratory tract tissue infected with human influenza A virus of the H3N2 subtype. Porcine SP-D has antiviral activity in these test systems. It is suggested that porcine SP-D may be used as a venue to develop a novel class of antiviral drugs. (C) 2014 Elsevier B.V. All rights reserved.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 22-26 |
| Number of pages | 5 |
| Journal | Virus Research |
| Volume | 181 |
| DOIs | |
| Publication status | Published - 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research programs
- EMC MM-04-27-01
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver